Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.

Vasily A IsakovVladimir ChulanovDzhamal AbdurakhmanovEduard BurnevichElena NurmukhametovaGalina KozhevnikovaNatalya GankinaSergey ZhuravelSvetlana RomanovaRobert H HylandSophia LuEvguenia S SvarovskaiaJohn McNallyDiana M BrainardVladimir IvashkinVyacheslav MorozovIgor BakulinMartin LaggingKonstantin ZhdanovOla Weiland

Published in: Infectious diseases (London, England) (2018)

Sofosbuvir/velpatasvir as a pangenotypic treatment for 12 weeks was highly effective in patients from Russia and Sweden infected with HCV genotypes 1, 2, or 3. Sofosbuvir/velpatasvir was safe and well-tolerated. Clinical trial number: ClinicalTrials.gov NCT02722837.

Keyphrases

hepatitis c virus
clinical trial
open label
human immunodeficiency virus
end stage renal disease
chronic kidney disease
phase ii
squamous cell carcinoma
study protocol
double blind
replacement therapy
locally advanced